Skip to main content

Byfavo Disease Interactions

There are 3 disease interactions with Byfavo (remimazolam).

Major

Benzodiazepines (applies to Byfavo) drug dependence

Major Potential Hazard, High plausibility. Applicable conditions: Drug Abuse/Dependence

Benzodiazepines have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages. However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms. Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines. It may be prudent to refrain from dispensing large quantities of medication to these patients. After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule. If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.

References

  1. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  2. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  3. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  5. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  6. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  7. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  8. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  9. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  10. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  11. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  12. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  13. (2011) "Product Information. Onfi (clobazam)." Lundbeck Inc
  14. (2020) "Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc
View all 14 references
Major

Benzodiazepines (applies to Byfavo) respiratory depression

Major Potential Hazard, High plausibility. Applicable conditions: Pulmonary Impairment, Asphyxia, Respiratory Arrest

Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with benzodiazepines should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used. Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.

References

  1. Iber FL, Livak A, Kruss DM (1992) "Apnea and cardiopulmonary arrest during and after endoscopy." J Clin Gastroenterol, 14, p. 109-13
  2. Cohen S, Khan A (1987) "Respiratory distress with use of lorazepam in mania." J Clin Psychopharmacol, 7, p. 199-200
  3. Donaldson D, Gibson G (1980) "System complications with intravenous diazepam." Oral Surg Oral Med Oral Patho, 49, p. 126-30
  4. Eldridge PR, Punt JA (1990) "Risks associated with giving benzodiazepines to patients with acute neurological injuries." Br Med J, 300, p. 1189-90
  5. Man GC, Hsu K, Sproule BJ (1986) "Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease." Chest, 90, p. 832-6
  6. Mendelson WB, Weingartner H, Greenblatt DJ, Garnett D, Gillin JC (1982) "A clinical study of flurazepam." Sleep, 5, p. 350-60
  7. (2002) "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn
  8. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  9. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  10. (2001) "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories
  11. (2001) "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation
  12. Pierce MW, Shu VS, Groves LJ (1990) "Safety of estazolam. The United States clinical experience." Am J Med, 88, s12-7
  13. Skatrud JB, Badr S, Begle RL, Juan D (1990) "Ventilatory response to single, high dose estazolam in healthy humans." J Clin Pharmacol, 30, p. 543-8
  14. Sullivan RJ, Jr (1989) "Respiratory depression requiring ventilatory support following 0.5 mg of triazolam." J Am Geriatr Soc, 37, p. 450-2
  15. (2001) "Product Information. Halcion (triazolam)." Pharmacia and Upjohn
  16. (2001) "Product Information. Dalmane (flurazepam)." Roche Laboratories
  17. Model DG, Berry DJ (1974) "Effects of chlordiazepoxide in respiratory failure due to chronic bronchitis." Lancet, 2, p. 869-70
  18. Dixon D (1985) "Respiratory depression following midazolam." Anaesthesia, 40, p. 922
  19. Yakel DL, Jr Whittaker SE, Elstad MR (1992) "Midazolam-induced angioedema and bronchoconstriction." Crit Care Med, 20, p. 307-8
  20. Berggren L, Eriksson I, Mollenholt P, Sunzel M (1987) "Changes in respiratory pattern after repeated doses of diazepam and midazolam in healthy subjects." Acta Anaesthesiol Scand, 31, p. 667-72
  21. Taylor JW, Simon KB (1990) "Possible intramuscular midazolam-associated cardiorespiratory arrest and death." DICP, 24, p. 695-7
  22. Munoz HR, Dagnino JA, Rufs JA, Bugedo GJ (1992) "Benzodiazepine premedication causes hypoxemia during spinal anesthesia in geriatric patients." Reg Anesth, 17, p. 139-42
  23. (2001) "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical
  24. (2001) "Product Information. Klonopin (clonazepam)." Roche Laboratories
  25. (2022) "Product Information. Prosom (estazolam)." Abbott Pharmaceutical
  26. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  27. Murphy PJ, Erskine R, Langton JA (1994) "The effect of intravenously administered diazepam, midazolam and flumazenil on the sensitivity of upper airway reflexes." Anaesthesia, 49, p. 105-10
  28. (2001) "Product Information. Doral (quazepam)." Wallace Laboratories
  29. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
  30. Berry RB, Kouchi K, Bower J, Prosise G, Light RW (1995) "Triazolam in patients with obstructive sleep apnea." Am J Respir Crit Care Med, 151, p. 450-4
  31. (2020) "Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc
View all 31 references
Major

Benzodiazepines (iv/im) (applies to Byfavo) prolonged hypotension

Major Potential Hazard, High plausibility. Applicable conditions: Shock, Altered Consciousness

Benzodiazepines should not be administered by injection to patients in shock or coma. The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.

References

  1. (2002) "Product Information. Valium (diazepam)." Roche Laboratories
  2. (2002) "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories
  3. (2001) "Product Information. Librium (chlordiazepoxide)." Roche Laboratories
  4. (2001) "Product Information. Versed (midazolam)." Roche Laboratories
  5. (2020) "Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc
View all 5 references

Byfavo drug interactions

There are 392 drug interactions with Byfavo (remimazolam).

Byfavo alcohol/food interactions

There is 1 alcohol/food interaction with Byfavo (remimazolam).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.